G1 Therapeutics Inc (NASDAQ:GTHX) – B. Riley lowered their FY2023 earnings per share estimates for G1 Therapeutics in a research report issued on Tuesday, August 13th. B. Riley analyst H. Polishetty now expects that the company will post earnings per share of $1.56 for the year, down from their prior estimate of $1.73.
A number of other equities analysts also recently commented on GTHX. JPMorgan Chase & Co. upgraded G1 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $38.00 to $45.00 in a report on Thursday, August 8th. Cowen restated a “buy” rating on shares of G1 Therapeutics in a report on Tuesday, June 18th. ValuEngine upgraded G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. BidaskClub upgraded G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, June 24th. Finally, Zacks Investment Research downgraded G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $61.00.
NASDAQ:GTHX opened at $37.40 on Wednesday. The stock’s 50 day moving average price is $27.71 and its 200 day moving average price is $21.84. G1 Therapeutics has a 52 week low of $13.87 and a 52 week high of $69.57. The company has a market capitalization of $1.50 billion, a P/E ratio of -14.61 and a beta of 2.66.
G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.09).
Hedge funds have recently made changes to their positions in the business. Bank of Montreal Can grew its holdings in G1 Therapeutics by 93,600.0% during the second quarter. Bank of Montreal Can now owns 2,811 shares of the company’s stock valued at $86,000 after purchasing an additional 2,808 shares during the last quarter. Legal & General Group Plc grew its holdings in G1 Therapeutics by 20.0% during the fourth quarter. Legal & General Group Plc now owns 4,060 shares of the company’s stock valued at $78,000 after purchasing an additional 676 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in G1 Therapeutics by 1,539.2% during the first quarter. BNP Paribas Arbitrage SA now owns 5,098 shares of the company’s stock valued at $85,000 after purchasing an additional 4,787 shares during the last quarter. NumerixS Investment Technologies Inc acquired a new position in G1 Therapeutics during the first quarter valued at approximately $98,000. Finally, Metropolitan Life Insurance Co. NY grew its holdings in G1 Therapeutics by 413.4% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,665 shares of the company’s stock valued at $147,000 after purchasing an additional 6,172 shares during the last quarter. Institutional investors own 73.58% of the company’s stock.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
See Also: How a Put Option Works
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.